Skip to content

Percutaneous Kyphoplasty Using Rotary Cutter in Osteoporotic Vertebral Fractures

Comparison of Kyphoplasty With and Without Rotary Cutter Subacute Osteoporotic Vertebral Fractures

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03850938
Enrollment
70
Registered
2019-02-22
Start date
2019-05-01
Completion date
2023-12-31
Last updated
2019-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spine Fracture

Keywords

fractures, compression, back pain, bone cements, kyphoplasty

Brief summary

Kyphoplasty(PKP) is performed under general anaesthesia in patients with osteoporotic vertebral compression fracture. The balloon is first placed into the fractured vertebra and inflated with contrast agent for height restoration. Then, the cement is injected into the cavity created by the balloon. As the diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones, refractures are often found in patients with conventional PKP. Furthermore, the loss of restored height of surgical vertebrae due to refracture in PKP. The investigators will applied a rotary cutter to destroy the structure of the cavity created by the balloon. Finally, the cement is injected, which may effectively interdigitates with the surrounding cancellous bone.

Interventions

DEVICEKyphoplasty with Rotary Cutter

The rotary cutter is applied before cement injection to destroy the structure around the cavity created by inflated balloon. Then, the rotary cutter will make the bone cement to support a wider range and to blend with the surrounding cancellous bones more densely.

DEVICEConventional Kyphoplasty

The cement is injected into the cavity created by PKP. The diffusion of cement can be interfered by closely barriers formed by surrounding cancellous bones.

Sponsors

Li Min
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient is able to undergo the vertebroplasty or balloon kyphoplasty procedure 2. Patient has read and sign the informed consent 3. Male or female, 50 years or older 4. Compressive and burst vertebral body fractures without any neurological deficit. 5. Persistent pain despite medical treatment according to VAS ≥ 5 or a last resort to morphine treatment

Exclusion criteria

1. Neurological signs related to the vertebral fracture to treat 2. Unmanageable bleeding disorder 3. History of surgical or percutaneous spine treatment except simple discectomy at a single or multiple vertebral levels with no residual pain. 4. Known allergy to bone cement 5. Local or generalized infection 6. Improvement of the symptoms of the patient with conservative management

Design outcomes

Primary

MeasureTime frameDescription
Back pain: Visual analogue scales systemup to 2 yearsMeasuring and comparing the post-operative back pain via Visual analogue scales system

Secondary

MeasureTime frameDescription
Refractureup to 2 yearsNumber of new vertebral fractures documented radiologically
Kyphotic angle and global thoracic and lumbar angulationsup to 2 years
The patterns of cement opacificationduring the procedure of PKPThe patterns of cement opacification were classified as solid patterns (cement forms a mass), trabecular patterns (cement spread along the fine bone trabeculae), and mixed patterns (cement forms a mass with spreading along the fine bone trabeculae)
Height of the treated vertebral bodyPreoperative, up to 2 yearsFollow-up of anterior, median and posterior height of the treated vertebral body, obtained by making an average of all measurements
Medico-economic follow-upup to 2 yearsCost of intervention; Cost of prescribed medicines; Cost of follow-up visits; Cost of subsequent hospitalization; Cost of complications.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026